Skip to Content

Generic Definity Availability

Medically reviewed by Drugs.com. Last updated on May 11, 2021.

See also: Generic Definity RT

Definity is a brand name of perflutren, approved by the FDA in the following formulation(s):

DEFINITY (perflutren - injectable;intravenous)

  • Manufacturer: LANTHEUS MEDCL
    Approval date: July 31, 2001
    Strength(s): 6.52MG/ML [RLD]

Has a generic version of Definity been approved?

No. There is currently no therapeutically equivalent version of Definity available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Definity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,583,207

    Patent expiration dates:

    • December 28, 2035
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
  • Patent 10,583,208

    Patent expiration dates:

    • March 16, 2037
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
  • Patent 10,588,988

    Patent expiration dates:

    • May 4, 2037
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
  • Methods for making ultrasound contrast agents
    Patent 9,789,210
    Issued: October 17, 2017
    Assignee(s): Lantheus Medical Imaging, Inc.

    Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

    Patent expiration dates:

    • March 16, 2037
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.